Verastem Inc (FRA:2VSA)
€ 3.7 -0.34 (-8.42%) Market Cap: 158.44 Mil Enterprise Value: 109.90 Mil PE Ratio: 0 PB Ratio: 13.49 GF Score: 32/100

Q1 2019 Verastem Inc Earnings Call Transcript

May 09, 2019 / 08:30PM GMT
Release Date Price: €20.95 (-3.38%)
Operator

Good afternoon and welcome to the Verastem Oncology Investor Conference Call on Thursday, May 9, 2019. (Operator Instructions) Please be advised that this call is being recorded at the company's request and will be available on the company's website for a period of 90 days from today.

At this time, I would like to introduce Mr. John Doyle, Vice President of Investor Relations and Finance at Verastem Oncology. Please go ahead, sir.

John Doyle

Welcome, everyone, and thanks for joining us this afternoon to discuss Verastem Oncology's financial results and corporate highlights for the first quarter of 2019. I'm joined today by Robert Forrester, our President and Chief Executive Officer; Joe Lobacki, our Chief Commercial Officer; Dan Paterson, our Chief Operating Officer; and Rob Gagnon, our Chief Financial Officer.

During today's call, Robert will provide some introductory comments, Joe will provide an update on the commercial COPIKTRA program, Dan will review a few clinical program development highlights, and Rob will discuss the highlights of our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot